MM's keeping PPS down to accumulate shares.

B will become at least the standard of care combined with Remdesivir.

In human lung epithelial cell line experiments performed at the RBL, Brilacidin in combination with Remdesivir, compared to Remdesivir-only treated conditions, showed a statistically significant and synergistic inhibition of SARS-CoV-2. Of particular note, overall viral load was reduced by 99.85 percent in one combination experiment, with remaining virus dropping to near undetectable levels.

Gilead will have to buy IPIX out to gain full SOC recognition. It would also give them control to do a B trial alone or stop one. Since B could be better alone.

So if trial results are as good as testing together there will be a lot of upside here. Of course just being in the trials it will bring a lot of attention to B,K and ipix so other opportunities would be forthcoming. PPS should soon reflect these facts.

Correct me if I am wrong, but I seem to remember they were going to do the fist 30 participants in the U.S. before they continued on with the 120. Of course they started the Russia trial 1st it seems and they have done 106 out of the 120. If they have completed the 1st 30 in the USA they may be going over the results before continuing on. At that point if it is positive they would get funds and maybe a partner. This could be why Leo is quiet.

You just can't stand losing , can you? Better learn how fast.

Profit taking this am only.Hold on and don't panic.

If you read the article posted it states Merck is still going forward with the two research molecules that are being researched. I don't see any effect on MYMX. Panic is a bitch.

Those of us that have been around and have any experience with governments and officials know they usually are the experts at anything but blowing their own horn, just to hear the sound. Excuse me for living. The current two vaccines are being ripped apart by facts arising during roll out. None will come out squeaky clean and most probably none will be right for everyone. So calm down, it is not too late, you aren't going to miss anything, just hope they do it right and everything will fall in place. One of the upsides is they and "B" and "K" are being exposed and that in itself could bring more opportunities and expose the importance of the science.
I myself am comfortable with the timing, nothing happens in business especially with the government involved and over holidays.Were close to getting this started and finally going to find out the truth about "B" and I think we will be very happy, at least enlightened.

Too much sand in your eyes over there? We still have two more days left in 2020 in my world. I know not much, but still time.

Unrealistic soul.Everything has moved along fairly fast so far. Most pharmas move at a snails pace.We have had gov't labs working on the filings and we all know how slow they are. Now we are going into a PH2 trial, whih=ch is amazing. Things should move a bit faster now. GLTA

Once they start the trial there will be a much bigger boost. Like Pfizer's vac they will find allergies and or problems with all the vacs coming. "b" works in 90+% ipix will be worth bilions. Getting a trial gets us one step closer to making bank.If the RBL trial results are even close we are money.Why would anyone sell now.

From the Merck recent $425M purchase of Oncolmmune.

An interim review took place once 146 patients in the placebo-controlled trial experienced clinical recovery. The review linked CD24Fc to a 60% higher probability of improvement in clinical status versus placebo and a more than 50% lower risk of death or respiratory failure. The median recovery time in the CD24Fc group was six days, compared to 10 days in the control cohort.

The results suggest CD24Fc may help a population failed by multiple other drugs. The World Health Organization recommends against the use of remdesivir in hospitalized patients, anti-SARS-CoV-2 antibodies have failed in the population and efforts to repurpose existing inflammatory disease drugs floundered. Dexamethasone is a rare example of a drug that improved outcomes in severe patients.

Some patients in the OncoImmune trial received drugs including dexamethasone and remdesivir. In patients who received corticosteroids, such as dexamethasone, median time to recovery was 15 days. Median recovery time in patients who received corticosteroids and CD24Fc was five days..

I also agree HT.A little patience here will pay off big time with trials start and soon therefater if B works anywhere near what RBL tests results were.

Do you believe China? LOL They are secretive about anything that would make them look bad.

Small retail investors are very fickle and when there is slow movement in the PPS they run as there easily scared off.

Once IPIX stars covid19 trials all the negative nellies will start bashing them. It will be interesting to see how the market reacts to that news. Nothing has changed in the fight against covid. Therapeutics ia most likely the answer.

Thanks Financial Times for being the only business news source to put this AM’s
$PFE
PR in perspective - studying 44,000 & Cherry Picked 94 patients -90% responded —Immune? no just responded . I have no PFE position.

IPIX losers panicking. Buy now or regret it later.

.2799 will look cheap as B progresses.

Now that info is coming out and the peer review will be completed then and only then will we know about grants, partners or other financing. At that point the stock will be trading over a buck or two.

We are not passed due for information as the RBL analyst just finished the review and it will take a few days to get that news out, after they write the peer review article. Then if good to great news the PPS will respond accordingly.

It has been stated by Dr, Fauci and others from the beginning one vaccine will not be enough to cure the virus and as Donny says a therapeutic is the best way to go and they are both right.We got lots of time as none of the vaccines in PH3 are better than the Convalescent blood one. Relax now that the analysis is completed we will soon find out it works and then all will come in time.
If B works over 50% they will have another news conference and this thing will fly.

Looks like they may want to take the PPS down a bit to get more shares with the imminent news coming any day now.

The contract was for 90 days from 5/19 for the research, which should have ended yesterday.

I take that back with 31 days in May and July the end date should have been yesterday the 17th.

Funding ($35K) was for 90 day research project started 5/19 and ends 8/19.
We should get a PR very soon.

May 19th they executed a 90 day research project that is coming to completion analyzing B to be submitted for peer review and used for trial design as well. A PR should be coming in a couple of days announcing the results. The 17th is the end date.

You have to be kidding. How in hell did you expect a grant without the RBL research finished and the peer review published? Before the trial begins they will get the grant to complete it.

Thank you Blue Fin this is the research I have been eluding to that will apply to the peer review article to be published in a medical journal and used for the grant and trial design input.

You obviously don't know much about how bio's work.You produce research and make them available to the public and then you get the attention from possible partners. Once the peer review is published then and only then will interest be forth coming. That is why investors are here as that is the big upside and start of interest from investors that will push the value of IPIX to new highs.

Everyone is anxiously waiting for an update like it will happen any day, but it has been PR'd that the analysis on B was for 3 months which ends in August and that will be the big PR coming. If B is validated as we expect things will move along rather quickly then. Peer review will be completed, Grant info will as well, so they will have the funds to start the trial in the 4th quarter as we have been told was the plan.

All the posts most of which are negative mean zilch until the research is completed and we know the outcome. Possibly something else will be PR'd, but I am not holding my breath, just my shares, until we hear the results.

And you know this how? Just because your timing hasn't been met? Too bad investing doesn't usually follow your timing, duh.

Therapeutics is the space to be in as no vaccine is going to achieve a high efficacy rate. Plus only 60% of people will get it and most likely it will take two shots and people won't like that. A high efficacy therapeutic will be the best choice. Why get vaccine if you don't get the virus anyway and you have a therapeutic that works well if you do get the virus. Say only 10% to 15% of people even get the virus, at max. Think about it.
B very well will be a great choice for a therapeutic. Vaccines won't be available until late 2021, so we have time to get some testing done.Peer review , grant and then PH2 and maybe Ph2/3. By the end of the year IPIX will be at over a buck, that is a pretty nice return of 300+%.

The trial could be a Ph2/3 trial.

I read it in a post that outlined the investigators protocol. I believe there was a PR on it.

So it states B is not effective and K doesn't work on tumors, this back in 2015 alleged in a lawsuit, but since then the FDA has allowed a PH2 for both and a PH3 for B after a successful PH2. King of shouts down your negative post and frivolous lawsuit doesn't it?

I agree, but they have to do the analysis to what protocol they will present for the trial.

Trump is now promoting therapeutics versus a vaccine as a preference.He stated this in the press conference yesterday. He would like a therapeutic that would be given once someone is hospitalized , that would take out the virus in just a few days and eliminate long hospital stays and possible deaths.
I believe more grants will be given to these candidates of which B is a prime example.

The researcher that is putting together the analysis has a date of 8/20 to finish it. I think that is what is holding up the peer review and any grants. Posts about this have been posted many times.

The meeting and the buyout rumor are totally different. The buyout meeting was a rumor from 2019.

The rumor was in 2019, not current.

I just read this in an article out today:

National Institutes of Health COVID-19 Treatment Guidelines, which clinicians who might be under-resourced and overwhelmed with spikes in COVID-19 cases rely on.

This is probably the reason it is taking a bit of time to get the peer review to the medical journal, but once it does and positive it should move the needle for IPIX.